1*MBBS Doctor, Department of Medicine, Mediciti Institute of Medical Sciences, Hyderabad, India
Email: shehzmaus106@gmail.com
For decades, clinicians managing refractory autoimmune diseases have operated within a frustrating therapeutic ceiling — escalating immunosuppression that controls rather than cures, and biologics that must be sustained indefinitely at the cost of infection, toxicity, and diminishing returns. Chimeric antigen receptor (CAR) T-cell therapy, developed originally to hunt down malignant B cells in haematological cancers, is now being turned toward this unmet need with results that few in the field anticipated so soon. Early clinical series — small in number but striking in consistency — show that a single infusion of CD19-directed CAR T cells can bring patients with refractory systemic lupus erythematosus (SLE), systemic sclerosis (SSc), and idiopathic inflammatory myopathies (IIM) into drug-free remission. Some have remained off all immunosuppression for more than two years. This is not incremental progress. It is a different kind of intervention entirely — one that appears to work not by suppressing the immune system indefinitely, but by depleting its autoreactive components and allowing something resembling a fresh immunological start.
This review traces the biology behind that possibility, examines what the clinical data actually show across individual disease contexts, considers how the technology is evolving through next-generation engineering, and confronts the real barriers — manufacturing, access, durability, resistance — that stand between early-phase promise and genuine clinical practice. As of mid-2025, 119 registered global trials are underway, the vast majority in Phase I. The science is moving fast; the standards it must meet are appropriately high.
Keywords: CAR T-cell therapy, autoimmune diseases, CD19, BCMA, systemic lupus erythematosus, immunological reset, systemic sclerosis, idiopathic inflammatory myopathy, allogeneic CAR T cells, cytokine release syndrome.
How to cite this article: Pirani S. CAR T-Cell Therapy For Refractory Autoimmune Diseases: Rethinking Immune Tolerance Through Cellular Engineering. Int J Drug Deliv Technol. 2026;16(7s): 954-963; DOI: 10.25258/ijddt.16.7s.102
Source of support: None
Conflict of interest: None